Eur J Nucl Med Mol I 2008, 35:1179–1191 CrossRef 22 Sujun L, Xun

Eur J Nucl Med Mol I 2008, 35:1179–1191.CrossRef 22. Sujun L, Xun L, Daxu L, et al.: Tumor inhibition and improved immunity in mice treated with flavone from Cirsium japonicum DC. International Immunopharmacology 2006, 6:1387–1393.CrossRef 23.

Jackson JG, St Clair P, Sliwkowski MX, et al.: Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 Captisol supplier monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 2004, 64:2601–2609.PubMedCrossRef 24. Vogel CL, Cobleigh MA, Tripathy D, et al.: Efficacy and safety of trastuzumab as a single H 89 datasheet agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 18:719–726.CrossRef 25. Perez EA: Cardiac toxicity of ErbB2-targeted therapies: what do we know? Clin Breast Cancer buy Doramapimod 2008, 8:114–120.CrossRef 26. Hattori K, Nishi Y, Nakamura S: Evaluation of cardiac dysfunction after herceptin treatment in patients with metastatic breast cancer by echocardiography. Rinsho Byori 2007, 55:120–125.PubMed 27. Vahid B, Marik PE: Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008, 133:528–538.PubMedCrossRef 28. Slamon DJ, Leyland-Jones B, et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses

HER2. N Engl J Med 2001, 344:783–792.PubMedCrossRef 29. Calabrich A, Fernandes Gdos S, Katz A: Trastuzumab: mechanisms of resistance and therapeutic opportunities. Oncology (Williston Park) 2008, 22:1250–1258.

30. Chen MH: Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue. Curr Cardiol Rep 2009, 11:167–174.PubMedCrossRef 31. Wang JN, Feng JN, Yua M: Structural analysis of the epitopes on erbB2 interacted with inhibitory or non-inhibitor monoclonal antibodies. Mol Immu nol 2004, 40:963–969.CrossRef 32. Tortora G, di Isernia G, Sandomenico C, et al.: Synergistic inhibition of growth and induction of apoptosis by 8-chloro-cAMP and paclitaxel or cisplatin in human cancer cells. Cancer Res 1997, 57:5107–5111.PubMed 33. Cummings MC, Winterford CM, Walker NL: Apoptosis. Am J Surg Pathol 1997, 21:88–101.PubMedCrossRef 34. Gillardon F, Wickert H, Zimmermann M: Up-regulation of however bax and down-regulation of bcl-2 is associated with kainate-induced apoptosis in mouse brain. Neurosci Lett 1995, 192:85–88.PubMedCrossRef 35. Adams JM, Cory S: The bcl-2 protein family: arbiters of cell surival. Science 1998, 281:1322–1326.PubMedCrossRef 36. Rakesh K, Mahitosh M, Allan L, et al.: Overexpression of HER2 Modulates Bcl-2, Bcl-XL, and Tamoxifen-induced Apoptosis in Human MCF-7 Breast Cancer Cells. Clin Cancer Res 1996, 2:1215–1219. 37. Zheng L, Weiya X, BingLiang F, et al.: Targeting HER-2/neu-overexpressing breast cancer cells by an antisense iron responsive element-directed gene expression. Cancer lett 2001, 174:151–158.

Comments are closed.